Disc Medicine (NASDAQ:IRON) Earns Overweight Rating from Can

Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $85.00 price objective on the stock. Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their target price on Disc […]

Related Keywords

Switzerland , United States , Swiss , Raymond James , Stifel Nicolaus , William Richard White , Charles Schwab Investment Management Inc , Morgan Stanley , Disc Medicine Company Profile , York Mellon Corp , Barclays Plc , Disc Medicine Inc , Cantor Fitzgerald , Swiss National Bank , Victory Capital Management Inc , Disc Medicine , Free Report , Moderate Buy , Medicine Stock Down , Get Free Report , Director William Richard White , New York Mellon Corp , Capital Management , National Bank , Charles Schwab Investment Management , Schwab Investment Management , Disc Medicine Daily ,